ArticleVaccines2022
Duration of Hepatitis B Vaccine-Induced Protection among Medical Students and Healthcare Workers following Primary Vaccination in Infancy and Rate of Immunity Decline.
Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06901362 (Seroprevalence and Vaccination Rate of Hepatitis B Virus and Varicella-zoster Virus Among Medical Students Under Immunizing Program), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Seroprevalence and Vaccination Rate of Hepatitis B Virus and Varicella-zoster Virus Among Medical Students Under Immunizing Program
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- HBV breakthrough infection in individuals born to mothers with HBV infection: a systematic review and meta-analysis.BMC public health · 2026Pooled it
- High cost of silence: Needlestick injuries and the persistence of hepatitis B virus risk among healthcare trainees.World journal of virology · 2026Article
- Review
- Barriers to compliance with hepatitis B vaccination: sociocultural and socioeconomic perspectives of pregnant women in the Bono East Region of Ghana.BMC pregnancy and childbirth · 2026Article
- Article
- Hepatitis B vaccine immunity in healthcare workers: Seroprotection and cellular immune signatures of waning response.Journal of family medicine and primary care · 2026Article
- Documented vaccination as proof of immunity compared to serology in medical students.Human vaccines & immunotherapeutics · 2025Article
- Level of antibody to hepatitis B surface antigen declined below 10 mIU/ml is still protective.NPJ vaccines · 2025Article
- Increasing Prevalence of Occult HBV Infection in Adults Vaccinated Against Hepatitis B at Birth.Vaccines · 2025Article
- Prevalence of hepatitis B surface antibody among previously vaccinated healthcare workers in Tashkent, Uzbekistan.Human vaccines & immunotherapeutics · 2024Article
- A Comprehensive Review of Hepatitis B Vaccine Nonresponse and Associated Risk Factors.Vaccines · 2024Review
- Hepatitis B and C infections among Japanese dental health workers: Insights from vaccination rates and screening results in the Oita prefecture.Clinical and experimental dental research · 2024Article
- Seroprevalence Study of Anti-HBs Antibodies in the General Population of Vojvodina, Serbia.Medicina (Kaunas, Lithuania) · 2024Article
- Impaired humoral immune response to hepatitis B vaccine in patients on maintenance hemodialysis.Saudi journal of biological sciences · 2023Article
- Presumed Protective Role for Anti-Hepatitis B Virus Antibodies Against COVID-19 Severe Cases: A Clinical Study ConfirmingFrontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Since the introduction of hepatitis B virus (HBV) vaccines, the numbers of HBV infections and complications have significantly decreased. However, the evidence on whether primary vaccination of infants confers lifelong immunity varies. We aimed to assess long-term immunity among healthcare workers and medical students, and the rate of decline of HBV surface antigen antibodies (anti-HBs). Hepatitis B status among participants born after 1 January 1992 was reviewed at Chulabhorn Royal Academy, Thailand. Participants were stratified by intervals since primary vaccination. HBV immunity was determined and analyzed as anti-HBs decline rate in participants with multiple follow-ups. A total of 464 participants were analyzed, with a median age of 23. Protective immunity against HBV (anti-HBs ≥ 10 mIU/mL) at 16-20, 21-25 and 26-28 years post-primary vaccination was 28%, 51.7% and 60%, respectively. The overall declining rate of anti-HBs was -42.39 mIU/mL per year. Participants with anti-HBs levels of >100-1000 mIU/mL at baseline had a faster decline rate than those with anti-HBs levels of 10-100 mIU/mL. Primary vaccination may not provide lifelong protection since HBV immunity deteriorates over time. Individuals with higher initial HBV immunity levels may experience a faster decline rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.